The Technical Analyst
Adamis Pharmaceuticals [ADMP]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Adamis Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.85% $0.775
America/New_York / 7 sep 2023 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 7.25 mill |
| EPS: | -10.14 |
| P/E: | -0.0764 |
| Earnings Date: | Nov 12, 2023 |
| SharesOutstanding: | 9.36 mill |
| Avg Daily Volume: | 3.11 mill |
| RATING 2023-10-03 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0764 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0764 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.434 - 0.814 ( +/- 30.44%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-10-23 | Dorbin John W. Jr. | Buy | 70 000 | Employee Stock Option (right to buy) |
| 2023-10-23 | Dorbin John W. Jr. | Buy | 0 | |
| 2023-10-16 | Cohen Seth | Buy | 151 416 | Employee Stock Option (right to buy) |
| 2023-10-16 | Cohen Seth | Buy | 0 | |
| 2023-09-15 | Versi Ebrahim | Buy | 729 200 | Common Stock |
| INSIDER POWER |
|---|
| 92.98 |
| Last 88 transactions |
| Buy: 1 947 813 | Sell: 1 308 563 |
Forecast:
01:40 - $0.184
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.775 (0.85% ) |
| Volume | 0.119 mill |
| Avg. Vol. | 3.11 mill |
| % of Avg. Vol | 3.84 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ADMP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ADMP
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
Last 10 Buy Signals
Latest Press Releases
2023-09-07 12:00:00 - Press Release
Adamis Pharmaceuticals Changes Name To Dmk Pharmaceuticals To Reflect New Strategic Focus
Company to begin trading under new ticker symbol “dmk” on september 8, 2023 company to begin trading under new ticker symbol “dmk” on september 8, 2023
2023-08-21 09:15:00 - Press Release
Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results And Provides Corporate Update
San diego, aug. 21, 2023 (globe newswire) -- adamis pharmaceuticals corporation (nasdaq: admp), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended june 30, 2023, and provided an update on recent corporate developments.
2023-08-04 13:43:00 - Press Release
Adamis Pharmaceuticals Announces Closing Of $8.0 Million Public Offering
San diego, aug. 04, 2023 (globe newswire) -- adamis pharmaceuticals corporation (nasdaq: admp), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase one share of common stock. each unit was sold at a public offering price of $1.35. the common warrants are immediately exercisable at a price of $1.35 per share and expire five years from the date of issuance. the shares of common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants were only purchasable together in this offering, but were issued separately and immediately separable upon issuance.
2023-08-02 08:30:00 - Press Release
Adamis Pharmaceuticals Announces Pricing Of $8.0 Million Public Offering
San diego, aug. 02, 2023 (globe newswire) -- adamis pharmaceuticals corporation (nasdaq: admp), a commercial-stage biopharmaceutical company, today announced the pricing of its public offering of 5,930,000 units at a public offering price of $1.35 per unit. each unit consists of one share of common stock (or a prefunded warrant in lieu thereof) and one warrant to purchase one share of common stock. the common warrants will be immediately exercisable at an exercise price of $1.35 per share and will expire five years from the date of issuance. the shares of common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance.
2023-07-28 08:30:00 - Press Release
Adamis Pharmaceuticals To Fund Zimhi® Clinical Study With University Of Leiden Opioid Expert
San diego, july 28, 2023 (globe newswire) -- adamis pharmaceuticals corporation (nasdaq: admp), a commercial-stage biopharmaceutical company, today announced the company has committed to fund an unrestricted research grant to the leiden university medical center (lumc) anesthesia and pain research unit. the funding will support the work of albert dahan, md, phd, a world expert on opioid-induced respiratory depression (opioid overdose) and professor of anesthesiology at the university. dr. dahan has been working with the fda since 2020 to understand better methods of reversing fentanyl overdoses.
Latest News
2023-05-15 18:32:06 - Seeking Alpha
Adamis Pharmaceuticals Corporation (ADMP) Q1 2023 Earnings Call Transcript
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP ) Q1 2023 Earnings Conference Call May 15, 2023 5:00 PM ET Company Participants Robert Uhl - MD, ICR Westwicke David Marguglio - CEO David Benedicto - CFO Eboo Versi - CEO, DMK Pharmaceuticals Conference Call Participants Operator Greetings, and welcome to Adamis Pharmaceuticals First Quarter 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
2023-03-17 16:50:24 - Seeking Alpha
Adamis Pharmaceuticals Corporation (ADMP) Q4 2022 Earnings Call Transcript
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP ) Q4 2022 Results Conference Call March 16, 2023 5:00 PM ET Company Participants Robert Uhl - MD, ICR Westwicke David Marguglio - CEO David Benedicto - CFO Dr. Eboo Versi - CEO, DMK Pharmaceuticals Conference Call Participants Operator Greetings, and welcome to the Adamis Pharmaceuticals Full Year 2022 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
2023-03-14 16:01:00 - GlobeNewsWire
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced that it will host an investor conference call on Thursday, March 16, 2023 at 2:00 p.m. PT to discuss its financial and operating results for the fourth quarter and full year 2022 as well as provide a corporate update. The company's fourth quarter and full year 2022 financial results news release is expected to be available after 1 p.m. PT on March 16, 2023, and on its website .
2023-02-28 10:45:24 - InvestorPlace
Adamis Pharmaceuticals (ADMP) Stock Wavers on Merger News
It's an unusual day for Adamis Pharmaceuticals (NASDAQ: ADMP ) stock traders, to say the least. That's because the company recently announced its intent to acquire DMK Pharmaceuticals.
2023-02-12 11:00:00 - PennyStocks
How to Diversify Your Penny Stock Investments
Use these tips for diversifying your investments in penny stocks The post How to Diversify Your Penny Stock Investments appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-11-14 22:03:03 - Seeking Alpha
Adamis Pharmaceuticals Corporation (ADMP) Q3 2022 Earnings Call Transcript
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP ) Q3 2022 Earnings Conference Call November 14, 2022 5:00 PM ET Company Participants Robert Uhl - Westwicke Partners David Marguglio - Co-Founder, CEO, President & Director David Benedicto - CFO Conference Call Participants Operator Good afternoon, ladies and gentlemen, and welcome to the Adamis Pharmaceuticals' Third Quarter 2020 Financial Results Conference Call. [Operator Instructions].
2022-10-21 13:27:31 - PennyStocks
10 Top Penny Stocks To Buy For Uner $1 Right Now
Penny stocks to watch under $1 right now. The post 10 Top Penny Stocks To Buy For Uner $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-10-20 14:28:46 - PennyStocks
Good Penny Stocks To Buy Now? 7 Under $1 To Watch This Week
2022-09-30 15:14:36 - Seeking Alpha
Adamis Pharmaceuticals: Managing A Position In A Company Diagnosed With Chronic Failure
Adamis Pharmaceuticals recently provided an update on Tempol's Phase II/III COVID-19 trial, which revealed the interim did not demonstrate statistical significance of its primary endpoint. The DSMB has recommended the company halt the trial. The company believes vaccination and the Omicron variant might have influenced the outcomes.
2022-08-11 19:00:10 - Seeking Alpha
Adamis Pharmaceuticals Corporation (ADMP) CEO David J. Marguglio on Q2 2022 Results - Earnings Call Transcript
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Robert Uhl - Managing Director, ICR Westwicke David J. Marguglio - Chief Executive Officer David Benedicto - Chief Financial Officer Ron Moss - Chief Medical Officer Conference Call Participants Operator Greetings and welcome to the Adamis Pharmaceuticals' Second Quarter 2022 Financial Results Conference Call.